Benzinga · Sep 4, 2026
Quince Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 15 To Regain Compliance
SEC.
QN
NASDAQ · QNCX
Quince Therapeutics, Inc.
Healthcare · Biotechnology
$28.59
Down-$0.96 (-3.25%)
Updated Sep 15, 2026, 4:48 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 245.56M
- P/E ratio
- -4.2
- Dividend yield
- 0.00%
- 52-week range
- $0.08 – $35.41
- Volume
- 33.57K
- Avg. volume
- 589.45K
Price performance
QNCX price history
1M range · 20 trading sessions · Daily adjusted prices
QNCX closed at $28.59 after 20 trading sessions, down 16.21% for the selected period.
- Last close
- $28.59
- Period change
- -16.21%
- Period low
- $28.59
- Period high
- $34.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $29.28 | $29.28 | $26.995 | $28.59 | 33.57K |
| Sep 11, 2026 | $28.88 | $30.44 | $28.88 | $29.55 | 11.34K |
| Sep 10, 2026 | $30.00 | $30.00 | $28.3101 | $28.96 | 3.63K |
| Sep 9, 2026 | $29.47 | $31.03 | $28.76 | $30.315 | 10.33K |
| Sep 8, 2026 | $31.88 | $31.88 | $29.005 | $29.50 | 12.71K |
| Sep 4, 2026 | $30.53 | $33.40 | $30.0001 | $31.32 | 37.86K |
| Sep 3, 2026 | $32.96 | $32.96 | $30.23 | $30.55 | 10.99K |
| Sep 2, 2026 | $32.92 | $33.05 | $31.96 | $32.15 | 15.48K |
| Sep 1, 2026 | $33.03 | $33.48 | $32.11 | $32.11 | 16.49K |
| Aug 31, 2026 | $34.04 | $34.04 | $31.4702 | $32.57 | 34.17K |
| Aug 28, 2026 | $32.91 | $35.34 | $31.8495 | $33.75 | 27.17K |
| Aug 27, 2026 | $31.99 | $32.86 | $29.95 | $32.50 | 16.52K |
| Aug 26, 2026 | $31.90 | $32.01 | $31.31 | $31.31 | 13.71K |
| Aug 25, 2026 | $32.40 | $33.69 | $30.93 | $30.93 | 17.45K |
| Aug 24, 2026 | $33.00 | $33.505 | $32.50 | $33.48 | 5.73K |
| Aug 21, 2026 | $32.77 | $34.085 | $32.57 | $33.93 | 9.54K |
| Aug 20, 2026 | $34.57 | $35.15 | $31.62 | $32.11 | 23.33K |
| Aug 19, 2026 | $32.89 | $35.23 | $31.25 | $34.57 | 23.4K |
| Aug 18, 2026 | $33.00 | $34.86 | $32.27 | $32.91 | 28.62K |
| Aug 17, 2026 | $34.95 | $35.41 | $33.08 | $34.12 | 38.99K |
Latest QNCX news
The latest Smart Investors Daily articles mentioning QNCX.
Stock researchCompany · Overview
QNCX research
Overview
Company profile and research snapshot.
Company profile
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 29, 2026 | Oppenheimer | Outperform | — |
| Jun 24, 2026 | Leerink Partners | Outperform | — |
| Jun 23, 2026 | Cantor Fitzgerald | Overweight | — |
| Jan 30, 2026 | D. Boral Capital | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026: Cantor Global Healthcare Conference: Fireside chat on Wednesday, September 9, 2026 at 2:45 p.m. ET H.C. Wainwright 28th Annual Global Inves
Benzinga · Aug 18, 2026
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Benzinga · Aug 14, 2026
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
